<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/outlook-therapeutics-inc-logo-1200x675.PNG/query-dj0yMDIwMTEyNDEyMTMzOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/outlook-therapeutics-inc-logo-1200x675.PNG/query-dj0yMDIwMTEyNDEyMTMzOQ"/></p>
<p>Outlook Therapeutics, Inc.（NASDAQ：OTLK）的股票獲得了 8 家研究公司的一致&#34;中等買入&#34;推薦，Marketbeat Ratings 報告。一位研究分析師給出了持有建議，另外七位對該公司發出了買入建議。過去一年內對該股票發佈報告的分析師中，平均 1 年價格目標為 46.43 美元。</p>
<p>獲取 <strong>Outlook Therapeutics</strong> 警報：</p>
<p>OTLK 最近成為多份研究報告的主題。Chardan Capital 將 Outlook Therapeutics 的評級從&#34;中性&#34;調高至&#34;買入&#34;，並設定了 60.00 美元的股價目標。BTIG Research 將 Outlook Therapeutics 的評級從&#34;中性&#34;調高至&#34;買入&#34;，並設定了 50.00 美元的股價目標。HC Wainwright 重申了&#34;買入&#34;評級，並設定了 30.00 美元的股價目標。最後，Capital One Financial 在一份報告中重申了對 Outlook Therapeutics 的&#34;超配&#34;評級。</p>
<p>查看我們對 Outlook Therapeutics 的最新股票報告</p>
<h2>對 Outlook Therapeutics 的對沖基金觀點</h2>
<p>一家對沖基金最近增加了其在 Outlook Therapeutics 股票中的持股。根據最新提交給證券交易委員會的 13F 文件，Scotia Capital Inc.在第三季度將其在 Outlook Therapeutics, Inc.（NASDAQ：OTLK）的持股增加了 420.9%。該基金在該季度購入了額外的 273,463 股，持有 338,439 股公司股票。截至最新的 SEC 提交，Scotia Capital Inc.擁有 Outlook Therapeutics 價值 75000 美元的股份，佔公司股份的 0.13%。11.20% 的股份由機構投資者持有。</p>
<h2>Outlook Therapeutics 股票表現</h2>
<p>OTLK 週五開盤價為 7.07 美元。股票的 50 天簡單移動平均線為 8.50 美元，200 天簡單移動平均線為 8.33 美元。該股票的市值為 1.6551 億美元，市盈率為-0.62，β係數為 0.28。Outlook Therapeutics 的 52 周最低價為 4.00 美元，52 周最高價為 40.60 美元。</p>
<h2>關於 Outlook Therapeutics（獲取免費報告</h2>
<p>Outlook Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於開發和商業化用於各種眼科適應症的單克隆抗體。其主要產品候選藥物是 ONS-5010，一種含有貝伐單抗的眼科製劑，目前正在進行濕性年齡相關性黃斑變性和其他視網膜疾病的 III 期臨牀試驗。</p>
<h2>參見</h2>
<ul>
<li>我們喜歡的五支股票勝過 Outlook Therapeutics</li>
<li>什麼是熱門股票？熱門股票解釋</li>
<li>MarketBeat 週迴顧-5/27-5/31</li>
<li>股息捕捉策略：你需要了解的</li>
<li>Foot Locker 的季度報告讓懷疑者四處奔跑</li>
<li>什麼是 WallStreetBets 以及他們瞄準的股票？</li>
<li>Costco Wholesale 可以創下新高；反彈即將到來</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw"/></p>
<p><em>此即時新聞警報由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 這家軍方支持的股票 “擁有” 人工智能市場（來自 Porter &amp; Company）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDA2"/></p>
<h2>現在是否值得投資 1000 美元購買 Outlook Therapeutics 股票？</h2>
<p>在考慮購買 Outlook Therapeutics 股票之前，您會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Outlook Therapeutics 並不在名單上。</p>
<p>儘管 Outlook Therapeutics 目前在分析師中有&#34;中等買入&#34;評級，但頂級分析師認為這五支股票更值得購買。</p>
<p>查看這五支股票</p>

塔吉特

OTLK

<p>Outlook Therapeutics, Inc.（納斯達克股票代碼：OTLK）獲得了分析師們的 “中等買入” 一致評級。該股票的 1 年價格目標為 46.43 美元，並獲得了七位分析師的買入推薦。該公司專注於開發和商業化用於眼科適應症的單克隆抗體。目前該股票的價格為 7.07 美元</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/outlook-therapeutics-inc-logo-1200x675.PNG/query-dj0yMDIwMTEyNDEyMTMzOQ" alt="" original-src="https://www.marketbeat.com/logos/outlook-therapeutics-inc-logo-1200x675.PNG?v=20201124121339"/></p>
<p>Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have earned a consensus recommendation of &#34;Moderate Buy&#34; from the eight research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $46.43.</p>
<div class="lb-trans"><p>Outlook Therapeutics, Inc.（NASDAQ：OTLK）的股票獲得了 8 家研究公司的一致&#34;中等買入&#34;推薦，Marketbeat Ratings 報告。一位研究分析師給出了持有建議，另外七位對該公司發出了買入建議。過去一年內對該股票發佈報告的分析師中，平均 1 年價格目標為 46.43 美元。</p>
</div><p>Get <strong>Outlook Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Outlook Therapeutics</strong> 警報：</p>
</div><p>OTLK has been the topic of a number of recent research reports. Chardan Capital raised Outlook Therapeutics from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $60.00 price objective on the stock in a report on Thursday, February 15th. BTIG Research raised Outlook Therapeutics from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $50.00 price objective on the stock in a report on Wednesday, March 27th. HC Wainwright reissued a &#34;buy&#34; rating and set a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday, May 17th. Finally, Capital One Financial reissued an &#34;overweight&#34; rating on shares of Outlook Therapeutics in a report on Friday, February 16th.</p>
<div class="lb-trans"><p>OTLK 最近成為多份研究報告的主題。Chardan Capital 將 Outlook Therapeutics 的評級從&#34;中性&#34;調高至&#34;買入&#34;，並設定了 60.00 美元的股價目標。BTIG Research 將 Outlook Therapeutics 的評級從&#34;中性&#34;調高至&#34;買入&#34;，並設定了 50.00 美元的股價目標。HC Wainwright 重申了&#34;買入&#34;評級，並設定了 30.00 美元的股價目標。最後，Capital One Financial 在一份報告中重申了對 Outlook Therapeutics 的&#34;超配&#34;評級。</p>
</div><p><strong>Check Out Our Latest Stock Report on Outlook Therapeutics</strong></p>
<div class="lb-trans"><p>查看我們對 Outlook Therapeutics 的最新股票報告</p>
</div><h2>Hedge Funds Weigh In On Outlook Therapeutics</h2>
<div class="lb-trans"><h2>對 Outlook Therapeutics 的對沖基金觀點</h2>
</div><p>A hedge fund recently raised its stake in Outlook Therapeutics stock. Scotia Capital Inc. grew its position in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 420.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 338,439 shares of the company's stock after purchasing an additional 273,463 shares during the quarter. Scotia Capital Inc. owned approximately 0.13% of Outlook Therapeutics worth $75,000 as of its most recent SEC filing. 11.20% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一家對沖基金最近增加了其在 Outlook Therapeutics 股票中的持股。根據最新提交給證券交易委員會的 13F 文件，Scotia Capital Inc.在第三季度將其在 Outlook Therapeutics, Inc.（NASDAQ：OTLK）的持股增加了 420.9%。該基金在該季度購入了額外的 273,463 股，持有 338,439 股公司股票。截至最新的 SEC 提交，Scotia Capital Inc.擁有 Outlook Therapeutics 價值 75000 美元的股份，佔公司股份的 0.13%。11.20% 的股份由機構投資者持有。</p>
</div><h2>Outlook Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Outlook Therapeutics 股票表現</h2>
</div><p>Shares of OTLK opened at $7.07 on Friday. The stock's 50-day simple moving average is $8.50 and its 200 day simple moving average is $8.33. The stock has a market capitalization of $165.51 million, a price-to-earnings ratio of -0.62 and a beta of 0.28. Outlook Therapeutics has a 52-week low of $4.00 and a 52-week high of $40.60.</p>
<div class="lb-trans"><p>OTLK 週五開盤價為 7.07 美元。股票的 50 天簡單移動平均線為 8.50 美元，200 天簡單移動平均線為 8.33 美元。該股票的市值為 1.6551 億美元，市盈率為-0.62，β係數為 0.28。Outlook Therapeutics 的 52 周最低價為 4.00 美元，52 周最高價為 40.60 美元。</p>
</div><h2>About Outlook Therapeutics (Get Free Report</h2>
<div class="lb-trans"><h2>關於 Outlook Therapeutics（獲取免費報告</h2>
</div><p>Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.</p>
<div class="lb-trans"><p>Outlook Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於開發和商業化用於各種眼科適應症的單克隆抗體。其主要產品候選藥物是 ONS-5010，一種含有貝伐單抗的眼科製劑，目前正在進行濕性年齡相關性黃斑變性和其他視網膜疾病的 III 期臨牀試驗。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Outlook Therapeutics</li>
<li>What Are Trending Stocks? Trending Stocks Explained</li>
<li>MarketBeat Week in Review – 5/27 - 5/31</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Foot Locker’s Quarter Sends Doubters Running</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>Costco Wholesale Can Hit New Highs; A Rebound Is Coming</li>
</ul>
<div class="lb-trans"><h2>參見</h2>
<ul>
<li>我們喜歡的五支股票勝過 Outlook Therapeutics</li>
<li>什麼是熱門股票？熱門股票解釋</li>
<li>MarketBeat 週迴顧-5/27-5/31</li>
<li>股息捕捉策略：你需要了解的</li>
<li>Foot Locker 的季度報告讓懷疑者四處奔跑</li>
<li>什麼是 WallStreetBets 以及他們瞄準的股票？</li>
<li>Costco Wholesale 可以創下新高；反彈即將到來</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OTLK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ This military-backed stock “owns” AI market (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 這家軍方支持的股票 “擁有” 人工智能市場（來自 Porter &amp; Company）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDA2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8006&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Outlook Therapeutics right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1000 美元購買 Outlook Therapeutics 股票？</h2>
</div><p>Before you consider Outlook Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買 Outlook Therapeutics 股票之前，您會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outlook Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Outlook Therapeutics 並不在名單上。</p>
</div><p>While Outlook Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Outlook Therapeutics 目前在分析師中有&#34;中等買入&#34;評級，但頂級分析師認為這五支股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五支股票</p>
</div>

Outlook Therapeutics, Inc.（納斯達克代碼：OTLK）獲得分析師的 “適度買入” 平均評級